Clinicopathologic and genetic characterization of invasive melanoma with BRAF V600K mutation: A study of 16 cases.
BRAF
V600E
V600K
low-CSD melanoma
melanoma
Journal
Journal of cutaneous pathology
ISSN: 1600-0560
Titre abrégé: J Cutan Pathol
Pays: United States
ID NLM: 0425124
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
28
04
2023
received:
24
02
2023
accepted:
07
05
2023
medline:
14
7
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
ppublish
Résumé
The clinicopathologic and genetic features of cutaneous melanoma with a BRAF V600K mutation are not well-known. We aimed to evaluate these characteristics in comparison with those associated with BRAF V600E. Real-time polymerase chain reaction (PCR) and/or the MassARRAY® system were used to detect BRAF V600K in 16 invasive melanomas and confirm BRAF V600E in another 60 cases. Immunohistochemistry and panel next-generation sequencing were used to evaluate protein expression and tumor mutation burden, respectively. The median age of melanoma patients harboring the BRAF V600K mutation (72.5 years) was higher than those with the BRAF V600E (58.5 years). The two groups also differed in sex (13/16 [81.3%] male in the V600K group vs. 23/60 [38.3%] in V600E) and in the frequency of scalp involvement (8/16 [50.0%] in V600K vs. 1/60 [1.6%] in V600E). The clinical appearance was similar to a superficial spreading melanoma. Histopathologically, non-nested lentiginous intraepidermal spread and subtle solar elastosis were observed. One patient (1/13, 7.7%) had a pre-existing intradermal nevus. Diffuse PRAME immunoexpression was seen in only one (14.3%) of seven tested cases. Loss of p16 expression was observed in all 12 cases (100%) analyzed. The tumor mutation burden was 8 and 6 mutations/Mb in the two tested cases. Melanoma carrying the BRAF V600K mutation showed the predominance on the scalp of elderly men, lentiginous intraepidermal growth, subtle solar elastosis, possible existence of intradermal nevus component, frequent loss of p16 immunoexpression, limited immunoreactivity for PRAME, and intermediate tumor mutation burden.
Sections du résumé
BACKGROUND
BACKGROUND
The clinicopathologic and genetic features of cutaneous melanoma with a BRAF V600K mutation are not well-known. We aimed to evaluate these characteristics in comparison with those associated with BRAF V600E.
METHODS
METHODS
Real-time polymerase chain reaction (PCR) and/or the MassARRAY® system were used to detect BRAF V600K in 16 invasive melanomas and confirm BRAF V600E in another 60 cases. Immunohistochemistry and panel next-generation sequencing were used to evaluate protein expression and tumor mutation burden, respectively.
RESULTS
RESULTS
The median age of melanoma patients harboring the BRAF V600K mutation (72.5 years) was higher than those with the BRAF V600E (58.5 years). The two groups also differed in sex (13/16 [81.3%] male in the V600K group vs. 23/60 [38.3%] in V600E) and in the frequency of scalp involvement (8/16 [50.0%] in V600K vs. 1/60 [1.6%] in V600E). The clinical appearance was similar to a superficial spreading melanoma. Histopathologically, non-nested lentiginous intraepidermal spread and subtle solar elastosis were observed. One patient (1/13, 7.7%) had a pre-existing intradermal nevus. Diffuse PRAME immunoexpression was seen in only one (14.3%) of seven tested cases. Loss of p16 expression was observed in all 12 cases (100%) analyzed. The tumor mutation burden was 8 and 6 mutations/Mb in the two tested cases.
CONCLUSIONS
CONCLUSIONS
Melanoma carrying the BRAF V600K mutation showed the predominance on the scalp of elderly men, lentiginous intraepidermal growth, subtle solar elastosis, possible existence of intradermal nevus component, frequent loss of p16 immunoexpression, limited immunoreactivity for PRAME, and intermediate tumor mutation burden.
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
BRAF protein, human
EC 2.7.11.1
PRAME protein, human
0
Antigens, Neoplasm
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
739-747Subventions
Organisme : JSPS KAKENHI
ID : JP22K06994
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Akbani R, Akdemir KC, Aksoy BA, et al. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681-1696. doi:10.1016/j.cell.2015.05.044
Kiuru M, Tartar DM, Qi L, et al. Improving classification of melanocytic nevi: BRAF V600E expression associated with distinct histomorphologic features. J Am Acad Dermatol. 2018;79:221-229. doi:10.1016/j.jaad.2018.03.052
Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-1890. doi:10.1093/jnci/djg123
Massi D, Carli P, Franchi A, Santucci M. Naevus-associated melanomas: cause or chance? Melanoma Res. 1999;9:85-91. doi:10.1097/00008390-199902000-00011
Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373:1926-1936. doi:10.1056/NEJMoa1502583
Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012;18:3242-3249. doi:10.1158/1078-0432.CCR-12-0052
Bucheit AD, Syklawer E, Jakob JA, et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013;119:3821-3829. doi:10.1002/cncr.28306
Stadelmeyer E, Heitzer E, Resel M, Cerroni L, Wolf P, Dandachi N. The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type. J Invest Dermatol. 2014;134:548-550. doi:10.1038/jid.2013.338
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. Lancet Oncol. 2014;15:323-332. doi:10.1016/S1470-2045(14)70012-9
Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;37:1867-1876. doi:10.1056/NEJMoa1408868
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;37:1877-1888. doi:10.1056/NEJMoa1406037
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;37:30-39. doi:10.1056/NEJMoa1412690
Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomized trials. Lancet Oncol. 2016;17:1743-1754. doi:10.1016/S1470-2045(16)30578-2
Schadendorf D, Long GV, Stroiakovski D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017;82:45-55. doi:10.1016/j.ejca.2017.05.033
Pires da Silva I, Wang KYX, Wilmott JS, et al. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. Clin Cancer Res. 2019;25:1272-1279. doi:10.1158/1078-0432.CCR-18-1680
Zengarini C, Mussi M, Veronesi G, Alessandrini A, Lambertini M, Dika E. BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies. Clin Exp Dermatol. 2022;47:1131-1136. doi:10.1111/ced.15113
Tachibana K, Goto K, Kukita Y, et al. BRAF immunoexpression can be intralesionally heterogenous but BRAF V600E mutation status is intralesionally homogeneous and interlesionally concordant in melanoma: a study of 140 lesions from 98 patients. Am J Dermatopathol. 2022;44:478-487. doi:10.1097/DAD.0000000000002146
Elder DE, Barnhill RL, Bastian BC, et al. Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. In: Elder DE, Massi D, Scolyer RA, Willemze R, eds. WHO Classification of Skin Tumours. IARC Press; 2018:66-71.
Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434-443. doi:10.1038/s41586-020-2308-7
Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526:68-74. doi:10.1038/nature15393
Tadaka S, Saigusa D, Motoike IN, et al. jMorp: Japanese multi omics reference panel. Nucleic Acids Res. 2018;46:D551-D557. doi:10.1093/nar/gkx978
Higasa K, Miyake N, Yoshimura J, et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J Hum Genet. 2016;61:547-553. doi:10.1038/jhg.2016.12
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. doi:10.1093/nar/gkq603
Hacker E, Olsen CM, Kvaskoff M, et al. Histologic and phenotypic factors and MC1R status associated with BRAFV600E, BRAFV600K, and NRAS mutations in a community-based sample of 414 cutaneous melanomas. J Invest Dermatol. 2016;136:829-837. doi:10.1016/j.jid.2015.12.035
Ponti G, Manfredini M, Tomasi A, Pellacani G. Distinctive clinical and dermoscopic features of BRAF V600K mutated melanomas. Br J Dermatol. 2015;172:1438-1440. doi:10.1111/bjd.13484
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. 2020;144:500-522.
Tan JM, Tom LN, Jagirdar K, et al. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive MAPK pathway activation. Br J Dermatol. 2018;178:191-198. doi:10.1111/bjd.15809
Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME expression in melanocytic tumors. Am J Surg Pathol. 2018;42:1456-1465. doi:10.1097/PAS.0000000000001134
Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. 2014;106:dju246. doi:10.1093/jnci/dju246
Yamazaki N, Yanaka R, Tsutsumida A, et al. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res. 2015;25:9-14. doi:10.1097/CMR.0000000000000091